Cryosurvival of Embryos From Dysmorphic Oocytes

This study has been completed.
Sponsor:
Information provided by:
V.K.V. American Hospital, Istanbul
ClinicalTrials.gov Identifier:
NCT00521443
First received: August 24, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted

August 24, 2007
August 24, 2007
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Cryosurvival of Embryos From Dysmorphic Oocytes
Not Provided

Various morphological abnormalities of human oocytes were reported to detrimentally affect embryo development. We observed development of frozen thawed embryos derived from oocytes with normal or abnormal morphological features to the blastocyst stage. Cytoplasmic abnormalities of the oocytes were found to negatively affect cryosurvival potential of the embryos.

Not Provided
Observational
Observational Model: Defined Population
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
  • Cryopreservation
  • Blastocyst
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
  • Control: Normal
    Embryos derived from morphologically normal MII oocytes
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Irregular Shapes
    Embryos derived from irregularly shaped oocytes.
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Large PVS
    Embryos derived from oocytes with large perivitelline space.
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Dark Zona
    Embryos derived from oocytes with dark zona pellucida
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Dark cytoplasm
    Embryos derived from oocytes with dark cytoplasm
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Vacuolar cytoplasm
    Embryos derived from oocytes with vacuolated cytoplasm
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Central granulation
    Embryos derived from oocytes with centrally granulated cytoplasm
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Double extra
    Embryos derived from oocytes with double extracytoplasmic abnormalities
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Double combined
    Embryos derived from oocytes with any combination of one extracytoplasmic and one cytoplasmic anomaly
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Double cytoplasmic
    Embryos derived from oocytes with any two cytoplasmic anomalies
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Triple extra
    Embryos derived from oocytes with triple extracytoplasmic anomaly
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
  • Case: Triple combined
    Embryos derived from oocytes with triple combined anomalies
    Intervention: Procedure: Cryopreservation, thawing and blastocyst culture
Balaban B, Ata B, Isiklar A, Yakin K, Urman B. Severe cytoplasmic abnormalities of the oocyte decrease cryosurvival and subsequent embryonic development of cryopreserved embryos. Hum Reprod. 2008 Aug;23(8):1778-85. Epub 2008 May 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Human embryos derived from morphologically normal or abnormal mature oocytes that fertilized normally by microinjection procedure.
  • Embryos were obtained from couples who refused to freeze their supernumerary embryos after fresh embryo transfer in an assisted reproduction treatment cycle.

Exclusion Criteria:

  • Embryos obtained after microinjection to immature oocytes taht were in vitro matured in culture.
  • Embryos obtained from abnormally fertilized zygotes.
Female
18 Years to 45 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
Turkey
 
NCT00521443
AH-05/04
Not Provided
Not Provided
V.K.V. American Hospital, Istanbul
Not Provided
Study Director: Basak Balaban, B.Sc. Assisted Reproduction Unit of the VKV American Hospital of Istanbul
V.K.V. American Hospital, Istanbul
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP